Success Metrics

Completion Rate

0%(0/1)

Active Trials

3(75%)

Terminated

1(25%)

Phase Distribution

Ph phase_3

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Terminated(1)

Detailed Status

Active, not recruiting2

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (50.0%)

Phase 32 (50.0%)

Trials by Status

terminated125%

active_not_recruiting250%

recruiting125%

Recent Activity

3 active trials

Showing 4 of 4

recruitingphase_3

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245

active_not_recruitingphase_2

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

NCT03806309

active_not_recruitingphase_2

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

NCT04713514

terminatedphase_3

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587

Clinical Trials (4)

Showing 4 of 4 trials

NCT06472245Phase 3

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Recruiting

NCT03806309Phase 2

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

Active Not Recruiting

NCT04713514Phase 2

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active Not Recruiting

NCT02654587Phase 3

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4